Interleukin-2 gene-modified tumor infiltrating lymphocytes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Interleukin-2 gene-modified tumor infiltrating lymphocytes, covering 2017-07-02 to 2017-07-02. Get the full timeline:
Most recent: Clinical Trial Update: Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma [Phase 1, Phase 2]